| Name | Title | Contact Details |
|---|
Elanco Animal Health Incorporated is a prominent American pharmaceutical company focused on developing, manufacturing, and marketing medicines and vaccinations for pets and livestock. Established in 1954 as a division of Eli Lilly and Company, Elanco became an independent entity in 2018 and has since grown to be one of the largest independent animal health companies worldwide. The acquisition of Bayer Animal Health in 2020 significantly expanded its size and global reach. Elanco offers a wide range of products aimed at enhancing animal health and productivity. This includes pharmaceuticals and vaccines for livestock and companion animals, nutritional solutions to improve feed efficiency, and data analytics through its Elanco Knowledge Solutions division. The company serves a diverse customer base, including farmers, veterinarians, pet owners, and agricultural stakeholders, all dedicated to improving animal health and food quality. Elancos mission emphasizes the importance of food and companionship in enriching life, reflecting its commitment to animal welfare and innovation in the animal health sector.
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta`s proprietary technology, utilizes CAAR T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company`s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please visit our website ( DesCAARTes™ Phase 1 Trial ). The Company`s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.
Allergene is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Botanix Pharmaceuticals is a biotechnology company listed on the ASX (ASX: BOT) with headquarters in Perth, Australia, and Philadelphia, USA. The company specializes in clinical-stage dermatology and antimicrobial treatments, focusing on synthetic cannabinoid-based therapies that utilize cannabidiol (CBD) and its proprietary skin-delivery technology, Permetrex™. The companys product pipeline includes several innovative therapies aimed at addressing common dermatological conditions. These include BTX 1503 for moderate-to-severe acne, BTX 1702 for rosacea, and BTX 1204A for moderate atopic dermatitis. Additionally, BTX 1801 targets infections in hemodialysis patients and other antimicrobial applications. All products leverage the Permetrex™ delivery system to enhance skin absorption, and Botanix is also exploring veterinary applications for atopic dermatitis. Botanix aims to improve patient outcomes by addressing unmet needs in dermatology and antimicrobial resistance, positioning itself as a leader in cannabinoid-based dermatological treatments.
Pioneering GMO and mycotoxin testing technologies and pushing boundaries forward in life science labs, grain markets and the global food supply chain.